⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 2024Open Access

Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Akihito Kawazoe Noboru Yamamoto Naotoshi Sugimoto Hisato Kawakami Takashi Oshima Kensei Yamaguchi Kaori Hino Motohiro Hirao Yukinori Kurokawa Takeshi Kawakami Masahiro Tsuda Hiroki Hara Shota Kaname Daiko Matsuoka Yohei Otake Keisuke Yasuda Takao Takase Shuya Takashima Taro Semba Kei Muro

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Fig S1. Patient dosing and responses over time (A) and anticancer medication received during follow-up (B)

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kawazoe et al. (2024) studied this question.

synapsesocial.com/papers/68e712deb6db64358768c055 https://doi.org/10.1158/1078-0432.25515828

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort2024
2Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort2024
3Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort2024
4Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort2024
5Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort2024

More related papers

Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort2024
Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort2024
Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates2024